Desmopressin (DDAVP) in Patients With Colorectal Cancer and Rectal Bleeding

Inclusion Criteria: * Patients \> 18 to \< 80 years of age who have signed the informed consent form * Histological diagnosis of rectal adenocarcinoma localized, locally advanced or metastatic * Treatment indication with chemotherapy and/or radiotherapy and/or surgery according to disease stage * Rectal bleeding associated with the primary tumor within 48 hours prior to study entry * Acceptable organ function to be able to participate in the study, performed within 14 days prior to admission; defined by the following parameters: * Electrocardiogram (ECG) without significant clinical abnormalities * Haemoglobin greater than or equal to 8 g/dL * Total leukocyte count greater than or equal to 4.0 x 10\^9/L * Absolute neutrophil count greater than or equal to 1.5 x 10\^9/L * Total platelet count greater to 100.0 x 10\^9/L * Total bilirubin less than or equal to 1.5 times the upper limit of normality (ULN) * Serum glutamic oxaloacetic transaminase (SGOT) and serum glutamic pyruvic transaminase (SGPT) less than or equal to 1.5 times upper limit of normality (ULN) * Creatinine clearance greater than 50 ml/min * Performance status (Eastern Cooperative Oncology Group \[ECOG\]) less than or equal to 2 * Patients with childbearing potential should use one of the following contraceptives methods: intrauterine devices, barrier methods and tubal ligation Exclusion Criteria: * Colorectal cancer without bleeding evidences * Pregnancy or lactation * Use of hormonal contrac…